Joanna Sadowska, PhD, EMBA’s Post

Here's Catenion's 10-year longitudinal study systematically clustering top biopharma companies into six performance phenotypes and dissecting patterns, key factors that positively influence R&D productivity. Key Takeaways: ♦ Creativity and innovation are easier to orchestrate in smaller units with less bureaucracy and high individual accountability ♦ Going deep vs broad: Having a solid TA focus and thinking well in advance about the ability to create spin off indications should not be neglected ♦ Focusing on key high-value assets, and ideally, having a 'pipeline in a product' is the best thing for R&D productivity ♦ Striking a balance between relying on core internal strengths for organic growth and leveraging external innovation through deals and M&As needs to be achieved You can read the full report here: https://lnkd.in/gnhMzesy

🚀 Top 10 Pharma Companies by Drug Pipeline 🚀 The competition is fierce in the pharma industry, but these companies are leading the charge with the most robust pipelines: Roche Pfizer AstraZeneca Eli Lilly Bristol Myers Squibb Novartis Johnson & Johnson Jiangsu Hengrui Pharmaceuticals Merck & Co. Sanofi 💡 Why Pipeline Analysis Matters: A strong drug pipeline reflects innovation, market leadership, and future growth. Pipeline analysis not only highlights the number of drugs but also gives insight into the therapeutic areas being targeted, the innovation pipeline, and potential blockbusters in the making. Pharma companies with deeper pipelines are better positioned to sustain long-term revenue growth, combat evolving healthcare challenges, and bring life-changing treatments to patients worldwide. 🔍 At the core of pipeline analysis is the ability to anticipate market needs, identify opportunities for expansion, and stay ahead of the curve in an ever-evolving healthcare landscape. Let’s continue to watch how these industry leaders shape the future of medicine! 🌟 #Pharma #DrugPipeline #HealthcareInnovation #Pharmaceuticals #CompetitiveAnalysis #MarketLeadership #FutureOfMedicine #PipelineAnalysis #ClinicalTrials

What are the factors that drive pharma R&D Productivity? Which pharma companies have done it best? Catenion has been systematically analyzing R&D Productivity for over 10 years. Now, our team has conducted a longitudinal study to answer these key questions, outlined by Catenion's Senior Partner Markus Thunecke. 💡A must-watch for everyone in the biopharma industry. Explore the in-depth report here: https://lnkd.in/gnhMzesy Companies featured: Novo Nordisk, AstraZeneca, Eli Lilly and Company, Novartis, Roche, Eisai US, Daiichi Sankyo, Inc., Pfizer, Sanofi, UCB, Merck KGaA, Darmstadt, Germany Bayer, Otsuka Pharmaceutical Co., Ltd., Takeda, Biogen, Gilead Sciences, AbbVie, Merck, Bristol Myers Squibb, GSK, Amgen, Johnson & Johnson, Astellas Pharma #Catenion #BiophamaConsulting #BiopharmaInnovation #RnDProductivity

📢 Happy Friday to all my contacts in the world of pharma! 💡 I am so excited to share this brand new state-of-the-art industry report - which provides a full update on the current state of pharmaceutical launches, examining why failures are occurring, and what strategies companies are implementing to overcome these challenges. This comprehensive analysis names key drugs, organisations, and insights to help you navigate regulatory hurdles and position your launches for success in this evolving landscape. Download your complimentary copy now of the 40+ page report for an in-depth look at: 💥 How AI is transforming pharma launch strategies 💊 Key therapeutic areas like oncology, immunology, and obesity treatments leading future launches 🎛 Navigating new regulatory challenges, including U.S. price controls and European reforms 👯 The critical role of cross-functional coordination in achieving launch success 📈 Why specialty drugs continue to dominate market growth ☀ The rise of independent launches by smaller biotech firms 💶 Addressing healthcare system capacity issues amid rising specialty drug costs 🔎 and so much more! Super proud to have commissioned this report, please share it far and wide to your colleagues/peers who might find it useful! #phlexsummit #phlex #pharmaceutical #launch #launchexcellence #therapeutics

Top Pharma Companies by Pipeline Size: Who's Leading the Charge? 💊🚨 The pharmaceutical industry in 2024 is undergoing a major shift, fueled by advances in biotechnology, precision medicine, and changing market demands. With a strong focus on oncology, neurological diseases, and biologics, R&D efforts are hitting new heights. This year’s pipeline reveals some key trends—dominated by innovative drug types and new players stepping up in the global R&D race. Curious who’s topping the list? Here are the Top 10 pharma companies by pipeline size: 1. Roche 2. Pfizer 3. AstraZeneca 4. Eli Lilly and Company 5. Bristol Myers Squibb 6. Novartis 7. Johnson & Johnson 8. Jiangsu Hengrui Pharmaceuticals 9. Merck & Co. 10. Sanofi Explore the full report below!👇🏻 https://bit.ly/3YejaFo #Pharma2024 #DrugDiscovery #BiotechInnovation #RDTrends #PharmaPipeline #Healthcare

Published my thoughts - the pharmaceutical industry is at a pivotal crossroads where soaring healthcare costs and demands for innovation are reshaping traditional investment paradigms. 💡 From precision medicine to value-based pricing, the future of pharma hinges on strategic adaptation to new market dynamics, making it crucial for stakeholders to rethink their approach to both investment and returns. #Pharma #HealthcareInnovation #IndustryTrends

Theranostics Market worth $4.3 billion by 2028 Download PDF Brochure:-https://lnkd.in/ddcdz7he The global theranostics market in terms of revenue was estimated to be worth $2.1 Billion in 2023 and is poised to reach $4.3 Billion by 2028, growing at a CAGR of 15.5% from 2023 to 2028.  𝐓𝐡𝐞 𝐜𝐨𝐦𝐩𝐚𝐧𝐢𝐞𝐬 𝐟𝐞𝐚𝐭𝐮𝐫𝐞𝐝 𝐢𝐧 𝐭𝐡𝐢𝐬 𝐫𝐞𝐩𝐨𝐫𝐭 𝐢𝐧𝐜𝐥𝐮𝐝𝐞 Advanced Accelerator Applications (France), Bayer Consumer Care AG (Germany), and GE HealthCare (US) among others. 𝐎𝐭𝐡𝐞𝐫 𝐜𝐨𝐦𝐩𝐚𝐧𝐢𝐞𝐬 𝐭𝐡𝐚𝐭 𝐚𝐫𝐞 𝐨𝐩𝐞𝐫𝐚𝐭𝐢𝐧𝐠 𝐢𝐧 𝐭𝐡𝐢𝐬 𝐦𝐚𝐫𝐤𝐞𝐭 𝐠𝐥𝐨𝐛𝐚𝐥𝐥𝐲 Novartis Pfizer Roche Johnson & Johnson AstraZeneca GSK Merck Sanofi Eli Lilly and Company AbbVie Amgen. Bristol Myers Squibb Gilead Sciences, TakedaPharmaceutical Nordics AB Biogen Regeneron Pharmaceuticals, Inc. Astellas Pharma Sumitomo Dainippon Pharma Daiichi Sankyo US Novo Nordisk Vertex Pharmaceuticals UCB CSL Alnylam Pharmaceuticals, Incyte Genmab Seagen. Illumina. Agilent Technologies, QIAGEN Guardant Health, Foundation Medicine, NanoString Technologies, Inc. Exact Sciences Bio-Techne #theranostics #personalizedmedicine #cancertreatment #biotech #precisionmedicine

The pharmaceutical industry is undergoing a period of remarkable transformation, driven by innovation, global expansion, and strategic advancements. Companies are continuously pushing boundaries to deliver healthcare solutions that improve lives worldwide 🌍. Industry giants like Sandoz, Teva Pharmaceuticals, SUN PHARMA, and Alvogen are at the forefront, leading the way in generics and biosimilars while also pioneering new treatments and approaches. These companies continue to shape the landscape with cutting-edge solutions and a strong commitment to accessible, high-quality healthcare. At the same time, Adalvo is carving out its own impressive niche. With a forward-thinking approach, strategic partnerships, and a commitment to agility and innovation, Adalvo is making waves in the industry. The company’s focus on driving global expansion, while maintaining a sharp focus on patient needs, places it among the most exciting players in the pharmaceutical space. Beyond these names, several other companies are also leading innovation, including: - Mylan (now part of Viatris) – A global leader in generics and over-the-counter products. - Bristol Myers Squibb – Pioneering breakthrough therapies in oncology and immunology. - Eli Lilly and Company – Innovating across multiple therapeutic areas, including diabetes and oncology. - Novartis – A global powerhouse in medicines and treatments across various therapeutic areas. As competition intensifies, these companies and many others are working tirelessly to improve patient outcomes, expand access to medicines, and create solutions for today’s most pressing healthcare challenges. What excites you most about the future of pharma? Which companies do you believe are leading the charge? Let’s connect and discuss! #Pharma #Innovation #HealthcareLeadership #GlobalGrowth #Generics #Biosimilars #AccessToMedicine #HealthcareInnovation

Leveraging Technology to Improve Drug Development Processes In the ever-evolving field of #pharmaceuticals, technology is playing a pivotal role in transforming the #drug development. Our findings delves into how GSK and Eli Lilly and Company's innovative #technologies are revolutionizing the #pharma industry. ➡️ For a more detailed and tailored Market Intelligence Report, contact us at sales@inferreconsult.com 𝗢𝘂𝗿 𝘀𝗲𝗿𝘃𝗶𝗰𝗲𝘀: ✔️ Pharma and Medtech market Access ✔️ Primary and Secondary Market Research ✔️ Business Development Partner ✔️ KOL Engagement ✔️ Market Intelligence Reports ✔️ Systematic Literature Review ✔️ Health Technology Assessments ✔️ Reimbursement and Pricing ✔️ Health Economic Outcome Research #DrugDevelopment #Pharmaceuticals #TechnologyInHealthcare #Innovation #AI #MachineLearning #Healthcare Pfizer Johnson & Johnson Roche Novartis Merck Group AstraZeneca AbbVie Sanofi Bristol Myers Squibb Actelion (now Janssen Pulmonary Hypertension)

See the link in the post below for a short summary of our webinar on early market access for biotech and investors #marketaccess #pharma #biotech